Adamas starts Phase III trial of ADS-5102 to treat PD patients with levodopa-induced dyskinesia
US-based Adamas Pharmaceuticals has started a pivotal Phase III clinical trial of its most advanced wholly owned product candidate ADS-5102 (amantadine HCl) for the treatment of patients with Parkinson's disease (PD) who have developed movement disor…
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Amantadine | Carbidopa/Levodopa | Clinical Trials | Dyskinesia | Parkinson's Disease | Pharmaceuticals | Symmetrel